-
1
-
-
42649145667
-
Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado, R., et al. (2008). Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26:1626-1634.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 1626-1634
-
-
Amado, R.1
-
2
-
-
0000092346
-
Repeated significance tests on accumulating data
-
Armitage, P., McPherson, C. K., Rowe, B. C. (1969). Repeated significance tests on accumulating data. Journal of the Royal Statistical Society Series A 132:235-244.
-
(1969)
Journal of the Royal Statistical Society Series A
, vol.132
, pp. 235-244
-
-
Armitage, P.1
McPherson, C.K.2
Rowe, B.C.3
-
3
-
-
78249260148
-
Aspects of modernizing drug development using scenario planning and evaluation
-
Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44:299-315.
-
(2010)
Drug Information Journal
, vol.44
, pp. 299-315
-
-
Benda, N.1
Branson, M.2
Maurer, W.3
Friede, T.4
-
4
-
-
54349104178
-
Unbiased estimation of selected treatment means in two-stage trials
-
Bowden, J., Glimm, E. (2008). Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 50:515-527.
-
(2008)
Biometrical Journal
, vol.50
, pp. 515-527
-
-
Bowden, J.1
Glimm, E.2
-
5
-
-
0036489056
-
Recursive combination tests
-
Brannath, W., Posch, M., Bauer, P. (2002). Recursive combination tests. Journal of the American Statistical Association 97:236-244.
-
(2002)
Journal of the American Statistical Association
, vol.97
, pp. 236-244
-
-
Brannath, W.1
Posch, M.2
Bauer, P.3
-
6
-
-
69949102133
-
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
-
Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28:1445-1463.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 1445-1463
-
-
Brannath, W.1
Zuber, E.2
Branson, M.3
Bretz, F.4
Gallo, P.5
Posch, M.6
Racine-Poon, A.7
-
7
-
-
33845891920
-
The design of simulation studies in medical statistics
-
Burton, A., Altman, D. G., Royston, P., Holder, R. L. (2006). The design of simulation studies in medical statistics. Statistics in Medicine 25:4279-4292.
-
(2006)
Statistics in Medicine
, vol.25
, pp. 4279-4292
-
-
Burton, A.1
Altman, D.G.2
Royston, P.3
Holder, R.L.4
-
8
-
-
84876448156
-
Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection
-
Carreras, M., Brannath, W. (2012). Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection. Statistics in Medicine 32:1677-1690.
-
(2012)
Statistics in Medicine
, vol.32
, pp. 1677-1690
-
-
Carreras, M.1
Brannath, W.2
-
9
-
-
84858794156
-
Inflation in the number of eligibility criteria for industry-sponsored phase ii cancer clinical trial: Illustration over a 20-year period
-
Clisant, S., Clermont, A., Adenis, A., Penel, N. (2012). Inflation in the number of eligibility criteria for industry-sponsored phase ii cancer clinical trial: Illustration over a 20-year period. Contemporary Clinical Trials 33:459.
-
(2012)
Contemporary Clinical Trials
, vol.33
, pp. 459
-
-
Clisant, S.1
Clermont, A.2
Adenis, A.3
Penel, N.4
-
12
-
-
77954875817
-
-
Food and Drug Administration. Available at: (accessed January 1, 2013)
-
Food and Drug Administration. (2010). Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf (accessed January 1, 2013).
-
(2010)
Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics
-
-
-
13
-
-
27744537954
-
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
-
Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7828.
-
(2005)
Clinical Cancer Research
, vol.11
, pp. 7872-7828
-
-
Freidlin, B.1
Simon, R.2
-
14
-
-
65649112030
-
Exploring changes in treatment effects across design stages in adaptive trials
-
Friede, T., Henderson, R. (2009). Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 8:62-72.
-
(2009)
Pharmaceutical Statistics
, vol.8
, pp. 62-72
-
-
Friede, T.1
Henderson, R.2
-
15
-
-
78249260149
-
Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis
-
Friede, T., Nicholas, R., Stallard, N., Todd, S., Parsons, N., Valds-Mrquez, E., Chataway, J. (2010). Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Information Journal 44:713-718.
-
(2010)
Drug Information Journal
, vol.44
, pp. 713-718
-
-
Friede, T.1
Nicholas, R.2
Stallard, N.3
Todd, S.4
Parsons, N.5
Valds-Mrquez, E.6
Chataway, J.7
-
16
-
-
84870869525
-
A conditional error function approach for subgroup selection in adaptive clinical trials
-
Friede, T., Parsons, N., Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309-4320.
-
(2012)
Statistics in Medicine
, vol.31
, pp. 4309-4320
-
-
Friede, T.1
Parsons, N.2
Stallard, N.3
-
17
-
-
33750884934
-
Confidentiality and trial integrity issues for adaptive designs
-
Gallo, P. (2006a). Confidentiality and trial integrity issues for adaptive designs. Drug Information Journal 40:445-450.
-
(2006)
Drug Information Journal
, vol.40
, pp. 445-450
-
-
Gallo, P.1
-
18
-
-
33745175516
-
Operational challenges in adaptive design implementation
-
Gallo, P. (2006b). Operational challenges in adaptive design implementation. Pharmaceutical Statistics 5:119-124.
-
(2006)
Pharmaceutical Statistics
, vol.5
, pp. 119-124
-
-
Gallo, P.1
-
19
-
-
33646245937
-
Adaptive designs in clinical drug development - An executive summary of the PhRMA working group
-
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. (2006). Adaptive designs in clinical drug development - An executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics 16:275-283.
-
(2006)
Journal of Biopharmaceutical Statistics
, vol.16
, pp. 275-283
-
-
Gallo, P.1
Chuang-Stein, C.2
Dragalin, V.3
Gaydos, B.4
Krams, M.5
Pinheiro, J.6
-
20
-
-
22544469981
-
Sungroup analyses in randomized clinical trials: Statistical and regulatory issues
-
Grouin, J. M., Coste, M., Lewis, J. (2005). Sungroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics 15:869-882.
-
(2005)
Journal of Biopharmaceutical Statistics
, vol.15
, pp. 869-882
-
-
Grouin, J.M.1
Coste, M.2
Lewis, J.3
-
21
-
-
33645762226
-
A sharper Bonferroni procedure for multiple tests of significance
-
Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
-
(1988)
Biometrika
, vol.75
, pp. 800-802
-
-
Hochberg, Y.1
-
22
-
-
0033566769
-
Statistical principles for clinical trials: ICH harmonized tripartite guideline
-
ICH E9 Expert Working Group
-
ICH E9 Expert Working Group. (1999). Statistical principles for clinical trials: ICH harmonized tripartite guideline. Statistics in Medicine 18:1905-1942.
-
(1999)
Statistics in Medicine
, vol.18
, pp. 1905-1942
-
-
-
23
-
-
79956157675
-
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
-
Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347-356.
-
(2011)
Pharmaceutical Statistics
, vol.10
, pp. 347-356
-
-
Jenkins, M.1
Stone, A.2
Jennison, C.3
-
25
-
-
34447264769
-
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
-
Jiang, W., Freidlin, B., Simon, R. (2007). Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99:1036-1043.
-
(2007)
Journal of the National Cancer Institute
, vol.99
, pp. 1036-1043
-
-
Jiang, W.1
Freidlin, B.2
Simon, R.3
-
26
-
-
70449529019
-
Discrete sequential boundaries for clinical trials
-
Lan, K. K. G., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659-663.
-
(1983)
Biometrika
, vol.70
, pp. 659-663
-
-
Lan, K.K.G.1
Demets, D.L.2
-
27
-
-
0032732411
-
Adaptive sample size calculations in group sequential trials
-
Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55:1286-1290.
-
(1999)
Biometrics
, vol.55
, pp. 1286-1290
-
-
Lehmacher, W.1
Wassmer, G.2
-
28
-
-
84879187854
-
Group sequential enrichment design incorporating subgroup selection
-
Magnusson, B. P., Turnbull, B. W. (2013). Group sequential enrichment design incorporating subgroup selection. Statistics in Medicine 32(16):2695-2714.
-
(2013)
Statistics in Medicine
, vol.32
, Issue.16
, pp. 2695-2714
-
-
Magnusson, B.P.1
Turnbull, B.W.2
-
29
-
-
84873817347
-
A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials
-
Millen, B. A., Dmitrienko, A., Truberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal 46(6):647-656.
-
(2012)
Drug Information Journal
, vol.46
, Issue.6
, pp. 647-656
-
-
Millen, B.A.1
Dmitrienko, A.2
Truberg, S.3
Shen, L.4
-
30
-
-
0034876356
-
Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and of classical group sequential approaches
-
Müller, H.-H., Schäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and of classical group sequential approaches. Biometrics 57:886-891.
-
(2001)
Biometrics
, vol.57
, pp. 886-891
-
-
Müller, H.-H.1
Schäfer, H.2
-
31
-
-
84857658991
-
An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection
-
Parsons, N., Friede, T., Todd, S., Valdes-Marquez, E., Chataway, J., Nicholas, R., and Stallard, N. (2012). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56:1150-1160.
-
(2012)
Computational Statistics and Data Analysis
, vol.56
, pp. 1150-1160
-
-
Parsons, N.1
Friede, T.2
Todd, S.3
Valdes-Marquez, E.4
Chataway, J.5
Nicholas, R.6
Stallard, N.7
-
32
-
-
77953105174
-
New strategies for treatment of kras mutant metastatic colorectal cancer
-
Prenen, H., Tejpar, S., Cutsem, E. V. (2010). New strategies for treatment of kras mutant metastatic colorectal cancer. Clinical Cancer Research 16(11):2921-2926.
-
(2010)
Clinical Cancer Research
, vol.16
, Issue.11
, pp. 2921-2926
-
-
Prenen, H.1
Tejpar, S.2
Cutsem, E.V.3
-
33
-
-
33750893179
-
Implementing adaptive designs: Logistical and operational considerations
-
Quinlan, J. A., Krams, M. (2006). Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 40:437-444.
-
(2006)
Drug Information Journal
, vol.40
, pp. 437-444
-
-
Quinlan, J.A.1
Krams, M.2
-
34
-
-
82255183905
-
Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
-
Rosenblum, M., Van Der Laan, M. J. (2011). Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika 98:845-860.
-
(2011)
Biometrika
, vol.98
, pp. 845-860
-
-
Rosenblum, M.1
Van Der Laan, M.J.2
-
35
-
-
67649345185
-
An improved Bonferroni procedure for multiple test of significance
-
Simes, R. J. (1986). An improved Bonferroni procedure for multiple test of significance. Biometrika 73:751-754.
-
(1986)
Biometrika
, vol.73
, pp. 751-754
-
-
Simes . R, J.1
-
36
-
-
34547529442
-
A method for testing a prespecified subgroup in clinical trials
-
Song, Y., Chi, Y. H. (2007). A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26(19):3535-3549.
-
(2007)
Statistics in Medicine
, vol.26
, Issue.19
, pp. 3535-3549
-
-
Song, Y.1
Chi, Y.H.2
-
37
-
-
77957962442
-
Adjusted significance levels for subgroup analyses in clinical trials
-
Spiessens, B., Debois, M. (2010). Adjusted significance levels for subgroup analyses in clinical trials. Contemporary Clinical Trials 31:647-656.
-
(2010)
Contemporary Clinical Trials
, vol.31
, pp. 647-656
-
-
Spiessens, B.1
Debois, M.2
-
38
-
-
78249241932
-
Efficiency of adaptive designs
-
Chow, S.-C., Pong, A., eds. Boca Raton, FL: Taylor & Francis
-
Stallard, N., Friede, T. (2010). Efficiency of adaptive designs. In: Chow, S.-C., Pong, A., eds. Handbook of Adaptive Designs in Pharmaceutical and Clinical Development. Boca Raton, FL: Taylor & Francis.
-
(2010)
Handbook of Adaptive Designs in Pharmaceutical and Clinical Development
-
-
Stallard, N.1
Friede, T.2
-
39
-
-
18444383925
-
Point estimates and confidence regions for sequential trials involving selection
-
Stallard, N., Todd, S. (2005). Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference 135:402-419.
-
(2005)
Journal of Statistical Planning and Inference
, vol.135
, pp. 402-419
-
-
Stallard, N.1
Todd, S.2
-
40
-
-
84885768838
-
Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression
-
Steinvorth, S., Röver, C., Schneider, S., Nicholas, R., Straube, S., Friede, T. (2013). Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression. Multiple Sclerosis Journal 19:1580-1586.
-
(2013)
Multiple Sclerosis Journal
, vol.19
, pp. 1580-1586
-
-
Steinvorth, S.1
Röver, C.2
Schneider, S.3
Nicholas, R.4
Straube, S.5
Friede, T.6
-
41
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
-
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., Wolf, M., Amado, R. G. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 25:1658-1664.
-
(2007)
Journal of Clinical Oncology
, vol.25
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.-L.7
Van Laethem, J.-L.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.G.12
-
42
-
-
66349125688
-
Adaptive patient enrichment designs in therapeutic trials
-
April
-
Wang, S.-J., Hung, H. M. J., O'Neill, R. T. (2009, April). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358-374.
-
(2009)
Biometrical Journal
, vol.51
, pp. 358-374
-
-
Wang, S.-J.1
Hung, H.M.J.2
O'neill, R.T.3
-
43
-
-
34648840242
-
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
-
Wang, S.-J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.
-
(2007)
Pharmaceutical Statistics
, vol.6
, pp. 227-244
-
-
Wang, S.-J.1
O'neill, R.T.2
Hung, H.M.J.3
-
44
-
-
79957438038
-
Design and analysis considerations in clinical trials with a sensitive subpopulation
-
Zhao, Y. D., Dmitrienko, A., Tamura, R. (2010). Design and analysis considerations in clinical trials with a sensitive subpopulation. Statistics in Biopharmaceutical Research 2:72-83.
-
(2010)
Statistics in Biopharmaceutical Research
, vol.2
, pp. 72-83
-
-
Zhao, Y.D.1
Dmitrienko, A.2
Tamura, R.3
|